Clinical trial
A Phase II Multi-Center, Randomized, Double-Blind, Active and Placebo-Controlled 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
NCT00115089 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Multi-Center, Randomized, Double-Blind, Active and Placebo-Controlled 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
- Lead sponsor
- Rigel Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2005
- Completion date
- September 30, 2005
- Enrollment
- 375
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.